NETRF promotes collaboration and resource sharing among funded researchers and the community, both crucial in advancing science.
Unique research resources created by NETRF funds must be readily available to qualified individuals, after publication. NETRF has partnered with several like-minded organizations that promote resource sharing.
Grant programs via partners
NETRF is dedicated to accelerating progress for better treatments and potential cures through partnerships with aligned organizations and private foundations.
Sponsored annual grants:
- North American Neuroendocrine Tumor Society (NANETS) The NANETS Basic/Translational Science Investigator Award is a two-year $100,000 award and will provide $50,000 in funding each year, which will be directed to the sponsoring institution. The purpose of the NANETS BTSI Award is to encourage scientists at the end of their fellowship who have secured a faculty appointment or scientists beginning their faculty appointment to pursue research focused on neuroendocrine tumors. Deadline for submission of the application is TBA.
- American Association for Cancer Research (AACR)
The grant provides $250,000 over two years for expenses related to the research project, which may include the salary and benefits of the grant recipient and any collaborators. This grant is available to independent junior and senior investigators to develop and study new ideas and innovative approaches that have direct application and relevance to neuroendocrine tumors. Proposed research may be in any discipline of basic, translational, or clinical cancer research. Deadline for submission 1/7/20.
- Education and Research Foundation for Nuclear Medicine and Imaging (ERF) The Nuclear Medicine Pilot Research Grant in Neuroendocrine Tumors (NETs) is designed to help a basic or clinical scientist in the early stages of their career conduct novel and innovative research that may be leveraged to lead to further funding from other foundations, corporations or government agencies. The grant will provide $100,000 for a two-year award. Second year funding will be contingent on satisfactory first-year progress reports. Deadline for submission 1/28/20.
In partnership with Rare Cancer Research Foundation (RCRF) and pattern.org, tissues from NET patients that are undergoing surgery are directed to the Cancer Cell Line Factory (CCLF) at the Broad Institute, for generation of NET cell lines.
The latest in NET News
A NETRF-funded clinical trial looks at a cancer vaccine called SurVaxM in neuroendocrine cancer to help slow or stop the spread of neuroendocrine tumors.
Latest in NET Cancer Research Neuroendocrine Tumor Research Foundation (NETRF) held its 11th Annual Research
NETRF Announces 2019 Neuroendocrine Cancer Research Funding Opportunities New award to fund early career investigators